JP2004536614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536614A5 JP2004536614A5 JP2003517208A JP2003517208A JP2004536614A5 JP 2004536614 A5 JP2004536614 A5 JP 2004536614A5 JP 2003517208 A JP2003517208 A JP 2003517208A JP 2003517208 A JP2003517208 A JP 2003517208A JP 2004536614 A5 JP2004536614 A5 JP 2004536614A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- isoform
- seq
- polypeptide according
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 238000000034 method Methods 0.000 claims 13
- 102000001708 Protein Isoforms Human genes 0.000 claims 11
- 108010029485 Protein Isoforms Proteins 0.000 claims 11
- 239000013604 expression vector Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 2
- 229940124639 Selective inhibitor Drugs 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 238000002823 phage display Methods 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 102000009097 Phosphorylases Human genes 0.000 claims 1
- 108010073135 Phosphorylases Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30927101P | 2001-08-01 | 2001-08-01 | |
| PCT/US2002/019319 WO2003012030A2 (en) | 2001-08-01 | 2002-06-19 | Isoform-selective inhibitors and activators of pde3 cyclic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536614A JP2004536614A (ja) | 2004-12-09 |
| JP2004536614A5 true JP2004536614A5 (enExample) | 2006-01-05 |
Family
ID=23197473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003517208A Pending JP2004536614A (ja) | 2001-08-01 | 2002-06-19 | Ｐｄｅ３環状ヌクレオチド・ホスホジエステラーゼのアイソフォーム選択的な阻害剤および活性化剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20030158133A1 (enExample) |
| EP (1) | EP1430140B1 (enExample) |
| JP (1) | JP2004536614A (enExample) |
| AT (1) | ATE481497T1 (enExample) |
| AU (1) | AU2002312543A1 (enExample) |
| DE (1) | DE60237696D1 (enExample) |
| WO (1) | WO2003012030A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9513288B2 (en) * | 2001-08-01 | 2016-12-06 | The United States Of America As Represented By The Department Of Veterans Affairs | Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases |
| DE60237696D1 (de) * | 2001-08-01 | 2010-10-28 | Univ Utah | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a |
| AU2003280241A1 (en) * | 2002-11-01 | 2004-05-25 | Mcmaster University | Multicomponent protein microarrays |
| WO2004071377A2 (en) * | 2003-02-17 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a) |
| CN1918175A (zh) | 2003-09-29 | 2007-02-21 | 托皮根药品公司 | 治疗包括炎症状况的疾病的寡核苷酸组合物和方法 |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| JP2005326165A (ja) * | 2004-05-12 | 2005-11-24 | Hitachi High-Technologies Corp | タンパク質相互作用解析のための抗タグ抗体チップ |
| ZA200804550B (en) | 2005-11-09 | 2009-08-26 | Combinatorx Inc | Methods, compositions, and kits for the treatment of medical conditions |
| WO2007054514A2 (en) * | 2005-11-14 | 2007-05-18 | Boehringer Ingelheim Vetmedica Gmbh | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure |
| AU2007252192B2 (en) | 2006-05-19 | 2013-10-17 | Topigen Pharmaceuticals Inc. | Oligonucleotides affecting expression of phosphodiesterases |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| US8354388B2 (en) * | 2007-04-10 | 2013-01-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Inhibitors of MRP4 for the treatment of vascular disorders |
| MX2011005444A (es) | 2008-11-25 | 2011-06-09 | Boehringer Ingelheim Vetmed | Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensibilizantes a iones de ca(2+) para el tratamiento de la cardiomiopatia hipertrofica. |
| CA2753362C (en) | 2009-02-24 | 2018-06-19 | The Scripps Research Institute | Reengineering mrna primary structure for enhanced protein production |
| WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| CA2755773A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina) |
| WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| MX2011010072A (es) | 2009-03-27 | 2011-10-06 | Merck Sharp & Dohme | Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia. |
| WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
| US9233997B2 (en) | 2010-08-26 | 2016-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| EP3167876B1 (en) | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| DK3021832T3 (da) | 2013-07-19 | 2021-05-25 | Boehringer Ingelheim Vetmedica Gmbh | Konserverede etherificerede cyclodextrinderivater indeholdende flydende vandig farmaceutisk sammensætning |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| ES2593210T3 (es) | 2013-12-04 | 2016-12-07 | Boehringer Ingelheim Vetmedica Gmbh | Composiciones farmacéuticas mejoradas de pimobendán |
| US9994830B2 (en) | 2014-07-15 | 2018-06-12 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods for modulating cyclic nucleotide-mediated signaling in cardiac myocytes and compositions |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| AU2022368907A1 (en) | 2021-10-20 | 2024-05-02 | University Of Copenhagen | Rejuvenation treatment of age-related white matter loss |
| EP4658294A2 (en) | 2023-02-02 | 2025-12-10 | University of Rochester | Competitive replacement of glial cells |
| WO2025090427A1 (en) | 2023-10-23 | 2025-05-01 | University Of Rochester | Glial-targeted relief of hyperexcitability in neurodegenerative diseases |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) * | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) * | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) * | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) * | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4215051A (en) * | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4366241A (en) * | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4883750A (en) * | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| JP2846018B2 (ja) | 1988-01-21 | 1999-01-13 | ジェネンテク，インコーポレイテッド | 核酸配列の増幅および検出 |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5624824A (en) * | 1989-03-24 | 1997-04-29 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
| US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US5614396A (en) * | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
| WO1992014447A1 (en) * | 1991-02-14 | 1992-09-03 | Baxter International Inc. | Binding of recognizing substances to liposomes |
| US5603872A (en) * | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
| US5358866A (en) * | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5596079A (en) * | 1991-12-16 | 1997-01-21 | Smith; James R. | Mimetics of senescent cell derived inhibitors of DNA synthesis |
| JPH07502898A (ja) * | 1992-01-13 | 1995-03-30 | デューク・ユニバーシティー | 酵素ｒｎａ分子 |
| CA2064683A1 (en) * | 1992-03-26 | 1993-09-27 | Krishna Mohan Rao Kallury | Formation of thermostable enzymes with extra-ordinary heat tolerance by immobilization on phospholipid matrices |
| US5279721A (en) * | 1993-04-22 | 1994-01-18 | Peter Schmid | Apparatus and method for an automated electrophoresis system |
| EP0736093B1 (en) * | 1993-12-23 | 2003-03-19 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL |
| US5986076A (en) * | 1994-05-11 | 1999-11-16 | Trustees Of Boston University | Photocleavable agents and conjugates for the detection and isolation of biomolecules |
| US6071394A (en) * | 1996-09-06 | 2000-06-06 | Nanogen, Inc. | Channel-less separation of bioparticles on a bioelectronic chip by dielectrophoresis |
| US5585069A (en) * | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
| US6068829A (en) * | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
| US6031071A (en) * | 1996-01-24 | 2000-02-29 | Biophage, Inc. | Methods of generating novel peptides |
| US5798246A (en) * | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
| US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
| US5948627A (en) * | 1997-05-30 | 1999-09-07 | One Lambda | Immunobead flow cytometric detection of anti-HLA panel-reactive antibody |
| CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| WO1999001139A1 (en) * | 1997-07-03 | 1999-01-14 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
| AU9509798A (en) * | 1997-09-25 | 1999-04-12 | University Of Florida | Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use |
| US6210892B1 (en) * | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6100037A (en) * | 1999-01-07 | 2000-08-08 | Incyte Pharmaceuticals, Inc. | Human cyclic nucleotide PDEs |
| US6146876A (en) * | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
| US6380161B1 (en) * | 1999-06-21 | 2002-04-30 | Inkine Pharmaceutical Company, Inc. | Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions |
| US6310047B1 (en) * | 1999-08-24 | 2001-10-30 | Virginia Commonwealth University | High affinity DNA binding compounds as adjuvants in antisense technology |
| AU3270301A (en) * | 1999-11-13 | 2001-05-30 | Icos Corporation | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity |
| AU2433001A (en) | 1999-12-14 | 2001-06-25 | University Of Utah Research Foundation | Two novel camp-specific phosphodiesterase (pde4b) isoforms and related technology |
| US6303374B1 (en) * | 2000-01-18 | 2001-10-16 | Isis Pharmaceuticals Inc. | Antisense modulation of caspase 3 expression |
| ATE266409T1 (de) * | 2000-04-13 | 2004-05-15 | Pfizer Prod Inc | Synergistische wirkung von glyburide und milrinone |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| DE60237696D1 (de) | 2001-08-01 | 2010-10-28 | Univ Utah | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a |
| US20090004668A1 (en) * | 2007-06-22 | 2009-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Pre-miRNA loop-modulated target regulation |
-
2002
- 2002-06-19 DE DE60237696T patent/DE60237696D1/de not_active Expired - Lifetime
- 2002-06-19 EP EP02739923A patent/EP1430140B1/en not_active Expired - Lifetime
- 2002-06-19 AU AU2002312543A patent/AU2002312543A1/en not_active Abandoned
- 2002-06-19 WO PCT/US2002/019319 patent/WO2003012030A2/en not_active Ceased
- 2002-06-19 AT AT02739923T patent/ATE481497T1/de not_active IP Right Cessation
- 2002-06-19 US US10/175,161 patent/US20030158133A1/en not_active Abandoned
- 2002-06-19 JP JP2003517208A patent/JP2004536614A/ja active Pending
-
2007
- 2007-01-18 US US11/654,858 patent/US8722866B2/en not_active Expired - Fee Related
-
2014
- 2014-03-27 US US14/227,426 patent/US9513289B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL144986A0 (en) | Rational selection of peptides presumed to have a specific function derived from identified nucleotide or peptide sequences | |
| CA2471762A1 (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway | |
| JP2006506942A5 (enExample) | ||
| CY1108568T1 (el) | Αναστολεας για διαγνωση και θεραπεια ασθενων με αιμορροφιλια α | |
| Vareli et al. | Nuclear distribution of prothymosin α and parathymosin: evidence that prothymosin α is associated with RNA synthesis processing and parathymosin with early DNA replication | |
| JP2002517193A5 (enExample) | ||
| Suzuki et al. | Calcium-activated neutral protease (CANP) and its biological and medical implications | |
| JP2005535289A5 (enExample) | ||
| JP2005501508A5 (enExample) | ||
| ATE205506T1 (de) | Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung | |
| Davis et al. | Phosphorylation of calmodulin in the first calcium-binding pocket by myosin light chain kinase | |
| WO2001036626A3 (en) | Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds | |
| ATE291033T1 (de) | Therapeutische peptide | |
| AU2006224318B2 (en) | Peptide stabilizer compounds and screening method | |
| JPWO2023008337A5 (enExample) | ||
| JP2004217634A5 (enExample) | ||
| JP2004513631A5 (enExample) | ||
| JP2005514010A5 (enExample) | ||
| IL145790A0 (en) | Methods and reagents for determining enzyme substrate specificity, and uses related thereto | |
| ATE538806T1 (de) | Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren | |
| CN103254290B (zh) | 基质金属蛋白酶-2多肽抑制剂及其应用 | |
| JP2008525427A5 (enExample) | ||
| Zoda et al. | Syntheses and activities of backbone‐side chain cyclic octapeptide ligands with N‐functionalized phosphotyrosine for the N‐terminal SH2‐domain of the protein tyrosine phosphatase SHP‐1 | |
| JP2003061662A5 (enExample) | ||
| JP2003066028A5 (enExample) |